Health Trials

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

ConditionLymphopenia
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
Age18+
SponsorImmunityBio, Inc.

About this trial

This is a protocol for expanded access use of nogapendekin-alfa inbakicept (NAI) in participants with lymphopenia induced by chemotherapy, immunotherapy, and/or radiation therapy who may benefit from its use, and who are ineligible to participate in a clinical trial using NAI. The primary objective of this protocol is to evaluate the reversal and maintenance of absolute lymphocyte count (ALC) with NAI.

Eligibility criteria

Qualifiers

Age ≥ 18 years old.

Chemotherapy and/or

Radiation therapy and/or

Immune checkpoint inhibitor therapy and/or any therapy investigator deems appropriate at that institution

Disqualifiers

Active uncontrolled autoimmune disease requiring immunosuppression

Participants with liquid tumors

Concurrent solid organ transplantation

Trial design

Treatments tested in this trial

  • nogapendekin-alfa inbakicept

Treatment groups

No treatment groups listed

Sponsors and collaborators

ImmunityBio, Inc.

Lead sponsor

Source ClinicalTrials.gov